The short version of MC4R fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-13. Anything still debated is marked as such rather than presented as settled.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-MSH |
| Molecular mass | Approximately 1025 Da | Peptide-scale molecule |
| Route | Subcutaneous injection | Intranasal form used in early research |
| Common synonyms | PT-141; bremelanotide acetate | Research code and salt form |
| Typical storage | 2-8 °C, protected from light | Unopened vial condition |
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Rapid evolutionary divergence, along with the multiple and parallel loss of orthologs in some lineages, can give the false appearance of the emergence of a novel gene from scratch. Recent syntheses highlight both rapid progress and ongoing debates in de novo gene research, including challenges in identification, functional validation, and links to microproteins and random-peptide experiments.
==== Corporate card ==== According to the Federal Court of Accounts (TCU), between January 2023 and April 2025 more than 55 million reais were spent by the Presidency with corporate cards. According to VEJA, of the entire amount, 99.55 percent are expenses classified as confidential, which prevents oversight bodies from evaluating how the amounts are being spent.
== Awards and honors == 1990 - Robert J. and Claire Pasarow Foundation Medical Research Award 1990 - American Association for Cancer Research - G.H.A. Clowes Memorial Award Archived 2017-10-24 at the Wayback Machine 1991 - Honorary doctorate in medicine from Lund University, Sweden 1995 - Nobel Fellow at the Karolinska Institutet in Stockholm 1997 - Gairdner Foundation International Award 1998 - Jacobaeus International Prize 2003 - Jubilee Lecturer, Biochemical Society 2005 - Japan Prize in Cell Biology 2012 - Thomson Reuters Citation Laureate Knight of the Order of the White Rose of Finland Commander of the Order of the Lion of Finland 2022 - Albert Lasker Award for Basic Medical Research. 2023 - Fellow of the American Association for Cancer Research. Member of National Academy of Sciences National Academy of Medicine American Academy of Arts and Sciences European Molecular Biology Organization
Sources: en.wikipedia.org
By 1987, companies selling lasers were claiming that they could treat pain, accelerate healing of sports injuries, and treat arthritis, but there was little evidence for this at that time. Mester originally called this approach "laser biostimulation", but it soon became known as "low-level laser therapy". With the adaptation of light emitting diodes it became known as "low-level light therapy"; to resolve confusion around the exact meaning of "low level", the term "photobiomodulation" arose as a synonym.
=== Available forms === Elagolix is available in the form of Orilissa 150 and 200 mg oral tablets. The 150 mg tablets are light pink, oblong, and film-coated with "EL 150" debossed on one side, while the 200 mg tablets are light orange, oblong, and film-coated with "EL 200" debossed on one side. The inactive ingredients in the tablets include mannitol, sodium carbonate monohydrate, pregelatinized starch, povidone, magnesium stearate, polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and a distinct color additive (carmine high tint in the 150 mg tablets and iron oxide red in the 200 mg tablets).
=== Hunger and satiety hormones === Unlike the surgical sleeve gastrectomy, the ESG does not appear to affect central appetite signaling through the hunger hormone, ghrelin. This is thought to be because the surgical sleeve removes the fundus, the primary site of ghrelin production, and the relatively thinner-walled fundus is avoided in the ESG for safety concerns. Furthermore, in cases where the fundus was sutured in ESG, this did not benefit weight loss outcomes.
==== Crown ether-type CSP ==== Crown ethers, like cyclodextrin-type CSPs contain a chiral cavity. Crown ethers are immobilized on the silica surface to form chiral stationary phase. Crown ethers contain oxygen atoms within the cavity. The cyclic structure that contains apolar ethylene groups between oxygen forms hydrophobic inner cavity. Cram et al., introduced CSP based on chiral crown ethers and accomplished separation of amino acid. The crucial chiral recognition principle underlying crown ether-based enantiomer separation is based on the formation of numerous hydrogen bonds between the protonated primary amino group of the analyte and the ether oxygens of the crown structure. This structural requirement confines the application of crown ether-type CSPs to chiral compounds having primary amino groups adjoining the chiral centers, such as amino acids, amino acid derivatives. Progress in the field of crown ether-type CSPs have been reviewed.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide that activates melanocortin receptors. It is given by injection and was approved in the United States in 2019 for a specific low-desire diagnosis in premenopausal women. It is not a hormonal therapy.
Earlier approaches were largely hormonal or psychological in focus, whereas this compound acts on central melanocortin signalling. It is not a vasodilator and does not share the mechanism of phosphodiesterase inhibitors. Head-to-head comparative data are limited.
Placebo responses in desire trials are large, so the average drug-placebo separation is small. Reporting therefore relies on validated questionnaires with statistical ranges. Individual responses vary widely.
Reported activity is highest at MC4R, with lower potency at MC1R and MC3R. The MC4R interaction is generally treated as the most relevant to its central effects. Selectivity is not absolute, and activity across the family is dose-dependent.